Biocon Biologics to acquire biosimilar assets from Viatris raising up to USD 3.335 billion in equity and cash


Biocon Biologics Ltd. , a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ) : VTRS ). Under the agreement, Biocon Biologics Ltd. (BBL) will acquire Viatris’ biosimilars business to create a fully integrated global biosimilars business. It is estimated that, in the next year, the revenues of this acquired company will be USD 1 billion. Viatris will receive compensation of up to USD 3.335 billion in cash and shares.

Read More

Next Post

Faron Obtains Debt Funding from IPF Partners

Faron Pharmaceuticals Ltd. (AIM: FARN) (First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, announces that it has entered into a secured debt agreement (“Funding Agreement”) with IPF Partners (“IPF”) to […]